|

EBV immunological agent Clinical Trials

1 actively recruiting trial

Also known as: Toripalimab 240mg

Pipeline

Phase 1: 1

Top Sponsors

  • West China Hospital1

Indications

  • Malignant Tumor1
  • Cancer1

Other1 trial

Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.